Oral dispersible vaccine comprising virosomes
The present disclosure is directed to oral vaccine dosage forms and processes for producing the oral vaccine dosage forms. The dosage forms include lipid-based vesicles (e.g., virosomes, liposomes) harboring an immunogenic amount of at least one vaccinal target molecule, with or without adjuvant. Specifically, Applicants discovered a combination of the composition of the liquid virosome concentrates, the composition of the base matrix for the solid dosage form formulation (excluding the virosome concentrate), and the manufacturing conditions for the dosage forms that can produce a freeze dried sublingual dosage form having physical robustness, particle and antigen integrity and stability.
1. An oral solid vaccine dosage form comprising:
lipid-based vesicles comprising an immunogenic amount of at least one target molecule;
5-20 wt. % of trehalose;
25-40 wt. % of gelatin; and
40-55 wt. % of mannitol.
2. The dosage form of claim 1 , wherein the lipid-based vesicles are virosomes or proteoliposomes.
3. The dosage form of claim 1 , wherein the dosage form comprises 10-15 wt. % of the trehalose.
4. The dosage form of claim 1 , wherein the dosage form comprises 33-37 wt. % of the gelatin.
5. The dosage form of claim 1 , wherein the gelatin comprises fish gelatin.
6. The dosage form of claim 5 , wherein the fish gelatin is high molecular weight fish gelatin.
7. The dosage form of claim 1 , wherein the dosage form comprises 45-50 wt. % of the mannitol.
8. The dosage form of claim 1 , wherein the virosomes are derived from the influenza virus membrane or other enveloped viruses.
9. The dosage form of claim 1 , wherein the at least one target molecule is present on the virosome.
10. The dosage form of claim 1 , wherein the at least one target molecule comprises an HIV-1 envelope derived antigen.
11. The dosage form of claim 10 , wherein the HIV-1 envelope derived antigen comprises HIV-1 PI peptide and/or HIV-1 recombinant gp41.
12. The dosage form of claim 1 , wherein the virosomes comprise adjuvant.
13. A method of inducing an immune response in a patient, the method comprising placing the dosage form of claim 1 in an oral cavity of a person in need of the immune response.
14. The method of claim 13 , wherein placement in the oral cavity is placement on or under the tongue or in the buccal or pharyngeal region.